Preventive healthcare is becoming one of healthtech’s most capital-intensive bets.
Neko Health has raised $700 million in Series C funding as it prepares to open its first US clinics in New York and other cities.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD also participated. David Ofer of O.G. Venture Partners is expected to join the company’s board, subject to regulatory approval.
Founded by Spotify co-founder Daniel Ek and CEO Hjalmar Nilsonne, Neko Health will use the capital to expand its clinics, clinical research, and proprietary medical hardware and software.
A one-hour preventive health assessment
Neko Health’s core product is a 60-minute, non-invasive, radiation-free health assessment.
The scan combines proprietary sensors with blood analysis to examine skin health, cardiovascular risk, metabolic indicators, and selected blood abnormalities. Results are prepared during the visit and discussed with a medical professional. The service currently costs £299 in the UK and SEK 2,750 in Sweden.
The company develops its hardware, software, and clinic experience internally. That vertical model gives Neko greater control over how data is collected, interpreted, and presented, but it also makes expansion more operationally demanding than scaling a software-only health product.
Recent additions include body-composition measurements and clinician review of wearable-device data. Neko is also rolling out upgraded devices designed to capture more detailed signals across skin, heart, and circulation.
Demand is becoming repeat behavior
Neko Health says more than 100,000 people have completed scans across Sweden and the UK, while more than 350,000 have registered or joined its waiting list.
The stronger commercial signal is repeat demand: the company reports that 75% of members book and prepay for another scan after their first appointment.
Neko also says three in four returning members previously identified with severe or life-threatening conditions were later in good health or had their condition under control. These findings are company-reported and should not be treated as independent clinical validation.
Why the US launch matters
The US offers a much larger market for direct-pay preventive healthcare, but it also introduces more complex regulatory, staffing, privacy, and clinical-operating requirements.
Neko’s opportunity is to turn preventive screening into a recurring healthcare service rather than a one-time premium test.
The pressure point will be evidence. The company must show that repeated scans improve health decisions without producing unnecessary anxiety, false positives, or avoidable follow-up care.
The larger signal is that healthtech is moving beyond apps and telemedicine toward vertically integrated clinical infrastructure.
Neko Health is betting that patients will pay for a recurring system designed to identify health risks before symptoms become serious.
